Tarsus Pharmaceuticals, Inc. (TARS) company profile
Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%
About Tarsus Pharmaceuticals
Biological Products, (No Diagnostic Substances), SIC 2836
The company is a commercial-stage biopharmaceutical business focused on developing and commercializing therapeutics, primarily targeting eye care and infectious disease prevention. Its primary commercial product is XDEMVY, an FDA-approved prescription ophthalmic solution that treats Demodex blepharitis by eradicating Demodex mites through GABA-Cl channel inhibition. Additionally, the business develops investigational formulations using the lotilaner active pharmaceutical ingredient, including a topical gel candidate for ocular rosacea and an oral tablet candidate designed for Lyme disease prophylaxis. Its commercialized offerings serve patients presenting with mite infestations and ocular conditions, prescribed directly by eye care professionals such as ophthalmologists and optometrists.
Commercial operations are primarily focused in the United States, where XDEMVY is actively marketed and sold via a dedicated specialty sales force. Beyond its core domestic presence, international expansion efforts include licensing partnerships in Greater China, alongside development and regulatory pursuits targeting approval in Europe and Japan. The provided text does not disclose the location of the company's headquarters or its founding year.
Summary of the business section of Tarsus Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Tarsus Pharmaceuticals, Inc.
- Headquarters
- Irvine, CA
- Address
- 15440 Laguna Canyon Road 92618
- Phone
- (949) 409-9820
- Website
- tarsusrx.com
- Employees
- 370, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst& Young LLP, Irvine, California
Stock & identifiers
- Ticker
- TARS
- Exchange
- Nasdaq
- IPO date
- Oct 16, 2020
- Shares outstanding
- 44M, Jul 30, 2026
- Public float
- $1.70B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1819790
- CUSIP
- 87650L103
- ISIN
- US87650L1035
- FIGI
- BBG00RB9BNQ7
- Share class FIGI
- BBG00RB9BNR6
- EIN
- 81-4717861
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Bobak R. Azamian | President/CEO and Board Chair, Director | 851,412 |
| Neera Clase | Chief Commercial Officer | 14,800 |
| Seshadri Neervannan | Chief Operating Officer | 79,007 |
| Elizabeth Yeu Lin | Chief Medical Officer | 16,177 |
| Jeffrey S. Farrow | See Remarks | 56,801 |
| Dianne C. Whitfield | Chief Human Resources Officer | 35,028 |
| Bryan Wahl | General Counsel | 63,959 |
| Aziz Mottiwala | Chief Commercial Officer | 61,480 |
| David E. I. Pyott | Director | 10,958 |
| William J. Link Phd | Director | 106,987 |
| Wendy L. Yarno | Director | 16,956 |
| Bhaskar Chaudhuri | Director | 11,654 |
| Scott W. Morrison | Director | 13,654 |
| Katherine Goodrich | Director | 2,233 |
| Andrew D. Goldberg | Director | 19,654 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $6.62M | $31.09M | $2.66M | $364 | $125 |
| FY2024 | $7.90M | $19.75M | $3.17M | $246 | $93 |
| FY2023 | $3.13M | $4.50M | $2.57M | $90 | $94 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Bobak Azamian President, Chief Executive Officer and Board Chairman | $726.33K | $2.65M | $2.65M | $555.70K | $36.18K | $6.62M | -16% |
| Jeffrey Farrow Chief Financial Officer and Chief Strategy Officer | $541.67K | $893.96K | $895.01K | $264.90K | $82.08K | $2.68M | -17% |
| Seshadri Neervannan Chief Operating Officer | $547.00K | $893.96K | $895.01K | $267.30K | $24.90K | $2.63M | -18% |
| Aziz Mottiwala Chief Commercial Officer | $529.25K | $983.36K | $984.52K | $260.10K | $32.30K | $2.79M | -11% |
| Bryan Wahl General Counsel | $500.83K | $893.96K | $895.01K | $245.50K | $24.90K | $2.56M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 16, 2020
- Offer price
- $16.00
- Securities offered
- 5,500,000
- Gross proceeds
- $88.00M
- Exchange
- Nasdaq
- First trading day
- Oct 16, 2020
- First-day close
- $20.58+28.6%
- Lock-up ends (est.)
- Apr 14, 2021
“The initial public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 370 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 10, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 16, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 13, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?